POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes

Article ID	Journal	Published Year	Pages	File Type
5952571	Chest	2016	9 Pages	PDF

Keywords

IPF DLCO RCT FDA Randomized controlled trial Food and Drug Administration diffusing capacity of the lung for carbon monoxide idiopathic pulmonary fibrosis

Related Topics

Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine

POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes

Authors

Christopher S. MD, FCCP, Steven D. MD, FCCP,